<p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - 獲取免費報告) 在週五交易前出現了跳空上漲。該股票之前收於 $2.95，但開盤價為 $3.10。NovaBay Pharmaceuticals 的股票最後交易價格為 $4.2880，成交量為 1,542,718 股。</p>
<h2>NovaBay Pharmaceuticals 股價上漲 84.6%</h2>
<p>該股票的 50 日移動平均線為 $1.37，200 日移動平均線為 $1.22。公司的市值為 6.8625 億美元，市盈率為 -0.57，貝塔值為 0.57。</p>
<h2>NovaBay Pharmaceuticals 分紅公告</h2>
<p>該公司最近宣佈了一項分紅，已於 9 月 29 日星期一支付。10 月 1 日星期三的登記股東獲得了 $0.80 的分紅。這代表了 3,791.0% 的分紅收益率。該分紅的除息日期為 9 月 30 日星期二。</p>
<h2>NovaBay Pharmaceuticals 的機構交易</h2>
<p>一些機構投資者和對沖基金最近買賣了 NBY 的股票。C2C Wealth Management LLC 在第二季度增持了 NovaBay Pharmaceuticals 的股份，增幅為 78.2%。C2C Wealth Management LLC 目前擁有 98,000 股該生物製藥公司的股票，價值 $57,000，此前在上個季度又購買了 43,000 股。Apollon Wealth Management LLC 在第三季度購買了 NovaBay Pharmaceuticals 的新股份，價值約 $35,000。最後，Ground Swell Capital LLC 在第三季度購買了 NovaBay Pharmaceuticals 的新股份，價值約 $25,000。目前，23.25% 的股票由機構投資者持有。</p>
<h2>關於 NovaBay Pharmaceuticals</h2>
<p>(獲取免費報告)</p>
<p>NovaBay Pharmaceuticals, Inc 是一家臨牀階段的生物技術公司，專注於開發和商業化新型非抗生素抗感染產品，旨在調節先天免疫反應。利用其專有的 Aganocide® 技術，該公司的合成抗微生物化合物能夠靶向並中和病原體，而不會導致抗生素耐藥性。NovaBay 的研發工作集中在眼科、皮膚科和傷口護理應用上，旨在解決感染控制和炎症管理中的未滿足需求。</p>
<p>該公司的主要商業產品包括 Avenova®，一種用於管理慢性瞼板腺功能障礙和瞼炎的眼瞼和睫毛清潔溶液，以及 NeutroPhase®，一種用於急性和慢性傷口灌洗的純次氯酸傷口和皮膚清潔劑。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 NovaBay Pharmaceuticals</li>
<li>3 只天然氣股票，提供優厚的分紅收益</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票説不是</li>
<li>最具波動性的股票，投資者需要了解的事項</li>
<li>2026 年的 4 只高潛力 ETF：小型股、太空股票等</li>
<li>內部人士賣出解釋：這能否影響你的投資選擇？</li>
<li>META 在科技下滑中上漲，特朗普的人工智能命令受到分析師讚揚</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 NovaBay Pharmaceuticals 嗎？</h2>
<p>在考慮 NovaBay Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買... 而 NovaBay Pharmaceuticals 並不在名單上。</p>
<p>雖然 NovaBay Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

NovaBay制藥

<p>NovaBay 製藥（NYSEAMERICAN:NBY）股價飆升 84.6%，開盤價為 3.10 美元，最新交易價為 4.2880 美元。該公司宣佈每股派息 0.80 美元，收益率達到 3,791.0%。機構投資者增加了持股。NovaBay 專注於非抗生素抗感染產品，主要產品包括 Avenova®和 NeutroPhase®。儘管近期股價大幅上漲，分析師目前對該股票的評級為持有</p>

<p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $2.95, but opened at $3.10. NovaBay Pharmaceuticals shares last traded at $4.2880, with a volume of 1,542,718 shares traded.</p>
<div class="lb-trans"><p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - 獲取免費報告) 在週五交易前出現了跳空上漲。該股票之前收於 $2.95，但開盤價為 $3.10。NovaBay Pharmaceuticals 的股票最後交易價格為 $4.2880，成交量為 1,542,718 股。</p>
</div><h2>NovaBay Pharmaceuticals Trading Up 84.6%</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 股價上漲 84.6%</h2>
</div><p>The stock has a 50 day moving average of $1.37 and a 200-day moving average of $1.22. The company has a market capitalization of $686.25 million, a P/E ratio of -0.57 and a beta of 0.57.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均線為 $1.37，200 日移動平均線為 $1.22。公司的市值為 6.8625 億美元，市盈率為 -0.57，貝塔值為 0.57。</p>
</div><h2>NovaBay Pharmaceuticals Dividend Announcement</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 分紅公告</h2>
</div><p>The business also recently announced a dividend, which was paid on Monday, September 29th. Stockholders of record on Wednesday, October 1st were issued a $0.80 dividend. This represents a dividend yield of 3,791.0%. The ex-dividend date of this dividend was Tuesday, September 30th.</p>
<div class="lb-trans"><p>該公司最近宣佈了一項分紅，已於 9 月 29 日星期一支付。10 月 1 日星期三的登記股東獲得了 $0.80 的分紅。這代表了 3,791.0% 的分紅收益率。該分紅的除息日期為 9 月 30 日星期二。</p>
</div><h2>Institutional Trading of NovaBay Pharmaceuticals</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 的機構交易</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of NBY. C2C Wealth Management LLC boosted its holdings in shares of NovaBay Pharmaceuticals by 78.2% during the 2nd quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 43,000 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in shares of NovaBay Pharmaceuticals in the third quarter worth about $35,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of NovaBay Pharmaceuticals in the third quarter worth about $25,000. 23.25% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近買賣了 NBY 的股票。C2C Wealth Management LLC 在第二季度增持了 NovaBay Pharmaceuticals 的股份，增幅為 78.2%。C2C Wealth Management LLC 目前擁有 98,000 股該生物製藥公司的股票，價值 $57,000，此前在上個季度又購買了 43,000 股。Apollon Wealth Management LLC 在第三季度購買了 NovaBay Pharmaceuticals 的新股份，價值約 $35,000。最後，Ground Swell Capital LLC 在第三季度購買了 NovaBay Pharmaceuticals 的新股份，價值約 $25,000。目前，23.25% 的股票由機構投資者持有。</p>
</div><h2>About NovaBay Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 NovaBay Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company's synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay's research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.</p>
<div class="lb-trans"><p>NovaBay Pharmaceuticals, Inc 是一家臨牀階段的生物技術公司，專注於開發和商業化新型非抗生素抗感染產品，旨在調節先天免疫反應。利用其專有的 Aganocide® 技術，該公司的合成抗微生物化合物能夠靶向並中和病原體，而不會導致抗生素耐藥性。NovaBay 的研發工作集中在眼科、皮膚科和傷口護理應用上，旨在解決感染控制和炎症管理中的未滿足需求。</p>
</div><p>The company's primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.</p>
<div class="lb-trans"><p>該公司的主要商業產品包括 Avenova®，一種用於管理慢性瞼板腺功能障礙和瞼炎的眼瞼和睫毛清潔溶液，以及 NeutroPhase®，一種用於急性和慢性傷口灌洗的純次氯酸傷口和皮膚清潔劑。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than NovaBay Pharmaceuticals</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 NovaBay Pharmaceuticals</li>
<li>3 只天然氣股票，提供優厚的分紅收益</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票説不是</li>
<li>最具波動性的股票，投資者需要了解的事項</li>
<li>2026 年的 4 只高潛力 ETF：小型股、太空股票等</li>
<li>內部人士賣出解釋：這能否影響你的投資選擇？</li>
<li>META 在科技下滑中上漲，特朗普的人工智能命令受到分析師讚揚</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in NovaBay Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 NovaBay Pharmaceuticals 嗎？</h2>
</div><p>Before you consider NovaBay Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 NovaBay Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovaBay Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買... 而 NovaBay Pharmaceuticals 並不在名單上。</p>
</div><p>While NovaBay Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 NovaBay Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

NovaBay 製藥（NYSEAMERICAN:NBY）股價跳空高開 - 現在是買入的好時機嗎？